Stockreport
NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript [Seeking Alpha]
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
147.78K Follower s Follow Play Earnings Call NovoCure Limited [NVCR] Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Ingrid Goldberg - Investor Relations Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Larry Biegelsen - Wells Fargo Jessica Fye - J.P. Morgan Vijay Kumar - Evercore ISI Emily Bodnar - H.C. Wainwright Operator Good day and thank you for standing by. Welcome to the NovoCure Q2 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Ing
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | NVCR | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
NVCR alerts
NVCR alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
NEWS
NEWS
- Gliosarcoma Market Intelligence Report 2026-2030 & 2035: Expansion of Molecular Testing and Increased Research Funding is Driving Industry Growth [Yahoo! Finance][Yahoo! Finance]
- Novocure to Report First Quarter 2026 Financial Results[Business Wire]
- Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer[Business Wire]
- Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer[Business Wire]
- NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance][Yahoo! Finance]
- More
NVCR
SEC Filings
SEC Filings
- 3/26/26 - Form SCHEDULE
- 3/26/26 - Form 8-K
- 3/5/26 - Form 4
- NVCR's page on the SEC website
- More